[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583991":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":34,"centralContacts":38,"locations":45,"responsibleParty":62,"collaborators":43,"id":64,"slug":43,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":43,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":43,"enrollmentInfo":72,"targetDuration":43,"studyType":75,"phases":76,"briefSummary":79,"conditions":80,"keywords":43,"overallStatus":48,"whyStopped":43,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Plan A","EXPERIMENTAL","ZG005（20mg\u002Fkg Q3W）+Gecacitinib（Gecacitinib is administered continuously until the end of treatment）",[13,14],"Biological: ZG005 for Injection","Drug: Gecacitinib Hydrochloride Tablets",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 1: Plan B","ZG005（20mg\u002Fkg Q3W）+Gecacitinib（Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21）",[13,14],[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","ZG005 for Injection","intravenous infusion",[9,16],[26],"ZG005",{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Gecacitinib Hydrochloride Tablets","Oral",[9,16],[33],"Gecacitinib",[35],{"name":36,"affiliation":5,"role":37},"Jason Wu","STUDY_CHAIR",[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Shuangyu Jia","CONTACT","+86-0512-57018310",null,"jiasy@zelgen.com",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":43,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"The First Affiliated Hospital, Zhejiang University School of Medicine","RECRUITING","Hangzhou","Zhejiang","China","CN",{"type":54,"coordinates":55},"Point",[56,57],120.16142,30.29365,{"lat":57,"lon":56},[60],{"name":61,"role":41,"phone":43,"phoneExt":43,"email":43},"Jie Jin",{"type":63,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100583991",false,"NCT06883526","Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma","A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I\u002FII Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma","Inclusion Criteria:\n\n* Fully understand this study and voluntarily sign the ICF；\n* Age ≥18 at ICF signing, regardless of gender；\n* Histologically confirmed relapsed or refractory lymphoma.\n\nExclusion Criteria:\n\n* Lymphoma with known CNS involvement；\n* Severe cardiovascular\u002Fcerebrovascular diseases.\n* Any other reason deeming the participant unsuitable for the study, as judged by the investigator.","ALL","18 Years",{"count":73,"type":74},60,"ESTIMATED","INTERVENTIONAL",[77,78],"PHASE1","PHASE2","PART 1:\n\n1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.\n2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma.\n\nPART 2:\n\nTo evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.",[81],"Lymphoma","2025-12-30",{"date":84,"type":85},"2026-01-05","ACTUAL",{"date":87,"type":85},"2025-05-16",{"date":89,"type":74},"2027-05",{"name":5,"class":6},1]